{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T20:02:13Z","timestamp":1774728133398,"version":"3.50.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The aim of this study was to evaluate the efficacy\/tolerability of a culture-guided approach in the eradication of <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic> and identify factors associated with antibiotic resistance\/treatment failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>This retrospective single-center study included patients who underwent culture-guided treatment for <jats:italic toggle=\"yes\">H. pylori<\/jats:italic> infection, after two ineffective eradication attempts, between October 2012 and December 2016. We assessed the following demographic and clinical data of the patients: sex, age, BMI, alcohol and tobacco consumption, history of dyspepsia, peptic ulceration and first-degree relatives with gastric cancer, antibiotic susceptibility results, treatment composition, tolerability, and success. The treatment success was confirmed by a monoclonal stool antigen test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Culture-guided treatment was performed in 42 patients (57% women, mean age\u00b1SD: 48.9\u00b111.4 years). The rates of antibiotic resistance were as follows: clarithromycin 86%, metronidazole 67%; levofloxacin 52%, tetracycline 2%, and amoxicillin and rifampicin 0%. Double resistance to clarithromycin and metronidazole was found in 59.5% of the patients. Most patients showed resistance to less than three antibiotics, but 31% were resistant to three or more. Intention-to-treat and per-protocol eradication rates were 59.5 and 61.5%. Adverse events occurred in 15 (35.7%) patients, but only two (4.8%) patients did not complete treatment because of adverse events. Only age more than 50 years was associated with resistance to three or more antibiotics. Having a first-degree relative with gastric cancer was associated with treatment failure and having a BMI of at least 25\u2009kg\/m<jats:sup>2<\/jats:sup> protected from failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Third-line culture-guided treatment often fails to eradicate <jats:italic toggle=\"yes\">H. pylori<\/jats:italic> infection. We need to find factors other than in-vitro antibiotic resistance to explain these suboptimal results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000000960","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T15:59:37Z","timestamp":1504713577000},"page":"1258-1263","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection"],"prefix":"10.1097","volume":"29","author":[{"given":"Samuel","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o-Bruno","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.gastro.2015.01.040","article-title":"Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits","volume":"148","author":"Graham","year":"2015","journal-title":"Gastroenterology"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.3748\/wjg.v20.i18.5205","article-title":"Culture-guided treatment approach for Helicobacter pylori infection: review of the literature","volume":"20","author":"Cammarota","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/hel.12061","article-title":"Sociodemographic determinants of prevalence and incidence of Helicobacter pylori infection in Portuguese adults","volume":"18","author":"Bastos","year":"2013","journal-title":"Helicobacter"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","article-title":"A report card to grade Helicobacter pylori therapy","volume":"12","author":"Graham","year":"2007","journal-title":"Helicobacter"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11695-012-0747-4","article-title":"Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery","volume":"23","author":"Cerqueira","year":"2013","journal-title":"Obes Surg"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12876-015-0245-y","article-title":"Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?","volume":"15","author":"Almeida","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","article-title":"H. pylori antibiotic resistance: prevalence, importance, and advances in testing","volume":"53","author":"M\u00e9graud","year":"2004","journal-title":"Gut"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/1469-0691.12701","article-title":"Helicobacter pylori antimicrobial resistance rates in the central region of Portugal","volume":"20","author":"Almeida","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ajcp\/108.5.504","article-title":"Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular?","volume":"108","author":"Engstrand","year":"1997","journal-title":"Am J Clin Pathol"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s11695-015-1920-3","article-title":"How effective is the quadruple concomitant Helicobacter pylori eradication therapy for obese patients undergoing gastric bypass surgery?","volume":"26","author":"Cerqueira","year":"2016","journal-title":"Obes Surg"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.3748\/wjg.v18.i40.5669","article-title":"Levofloxacin amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line","volume":"18","author":"Di Caro","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"9898","DOI":"10.3748\/wjg.v20.i29.9898","article-title":"Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance","volume":"20","author":"Papastergiou","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0009-9236(99)70075-5","article-title":"CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans","volume":"65","author":"Furuta","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1046\/j.1365-2036.2001.01108.x","article-title":"Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH","volume":"15","author":"Shirai","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1572-0241.2003.07427.x","article-title":"The clinical role of cytochrome p450 genotypes in Helicobacter pylori management","volume":"98","author":"Sapone","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1523-5378.2008.00643.x","article-title":"Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis","volume":"13","author":"Zhao","year":"2008","journal-title":"Helicobacter"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"e62162","DOI":"10.1371\/journal.pone.0062162","article-title":"Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials","volume":"8","author":"Tang","year":"2013","journal-title":"PLoS One"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2036.2012.05211.x","article-title":"Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection","volume":"36","author":"McNicholl","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2036.2000.00685.x","article-title":"Efficacy of a multistep strategy for Helicobacter pylori eradication","volume":"14","author":"Gasbarrini","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1365-2036.2004.01910.x","article-title":"High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection","volume":"19","author":"Cammarota","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1365-2036.2000.00833.x","article-title":"Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients","volume":"14","author":"Gomoll\u00f3n","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0210-5705(02)70283-5","article-title":"Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture guided study","volume":"25","author":"Vicente","year":"2002","journal-title":"Gastroenterol Hepatol"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1523-5378.2003.00145.x","article-title":"Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing","volume":"8","author":"Kim","year":"2003","journal-title":"Helicobacter"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/hel.12244","article-title":"Editorial \u2013 avoiding unethical Helicobacter pylori clinical trials: susceptibility-based studies and probiotics as adjuvants","volume":"20","author":"Graham","year":"2015","journal-title":"Helicobacter"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000381419","article-title":"Potent gastric acid inhibition over 24\u2009h by 4-times daily dosing of esomeprazole 20\u2009mg","volume":"91","author":"Sahara","year":"2015","journal-title":"Digestion"},{"key":"R28-20230916","doi-asserted-by":"crossref","first-page":"10644","DOI":"10.3748\/wjg.v21.i37.10644","article-title":"Are probiotics useful in Helicobacter pylori eradication?","volume":"21","author":"Homan","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R29-20230916","doi-asserted-by":"crossref","first-page":"e2831","DOI":"10.1097\/MD.0000000000002831","article-title":"The association of age and antibiotic resistance of Helicobacter pylori: a study in Jiaxing City, Zhejiang Province, China","volume":"95","author":"Ji","year":"2016","journal-title":"Medicine"},{"key":"R30-20230916","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"R31-20230916","first-page":"141","article-title":"The clinical significance of GastroPanel in diagnostics of Helicobacter pylori eradication efficiency in patients with dyspepsia with correlation of family history of gastric cancer","volume":"35","author":"Adamczyk","year":"2013","journal-title":"Pol Merkur Lekarski"},{"key":"R32-20230916","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s11695-008-9477-z","article-title":"The eradication of Helicobacter pylori is affected by body mass index (BMI)","volume":"18","author":"Abdullahi","year":"2008","journal-title":"Obes Surg"},{"key":"R33-20230916","first-page":"26","article-title":"Body mass index and per capita income influence duodenal ulcer healing and H. pylori eradication whilst dietary factors play no part","volume":"29","author":"Singh","year":"2008","journal-title":"Trop Gastroenterol"},{"key":"R34-20230916","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1592\/phco.27.8.1081","article-title":"Antimicrobial dosing considerations in obese adult patients","volume":"27","author":"Pai","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R35-20230916","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics implications for drug therapy","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R36-20230916","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00134-003-2059-6","article-title":"Dosing of medications in morbidly obese patients in the intensive care unit setting","volume":"30","author":"Erstad","year":"2004","journal-title":"Intensive Care Med"},{"key":"R37-20230916","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2036.2003.01396.x","article-title":"Risk factors for failure of Helicobacter pylori therapy \u2013 results of an individual data analysis of 2751 patients","volume":"17","author":"Broutet","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-20230916","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjmed.2005.10.003","article-title":"Smoking increases the treatment failure for Helicobacter pylori eradication","volume":"119","author":"Suzuki","year":"2006","journal-title":"Am J Med"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042737-201711000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T15:08:35Z","timestamp":1694876915000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-201711000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000000960","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}